More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial

Retina. 2010 Jan;30(1):1-5. doi: 10.1097/IAE.0b013e3181cde727.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / adverse effects*
  • Antibodies, Anti-Idiotypic / blood*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Clinical Trials as Topic
  • Drug Stability*
  • Humans
  • Infliximab
  • Injections
  • Macular Degeneration / drug therapy
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Uveitis / drug therapy
  • Vitreous Body

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Tumor Necrosis Factor-alpha
  • Infliximab